Curanex Pharmaceuticals Inc Increase (Decrease) in Prepaid Expense
Curanex Pharmaceuticals Inc (CURX) reported Increase (Decrease) in Prepaid Expense of -$4.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-14
- Curanex Pharmaceuticals Inc increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was -$2.22M.
- Curanex Pharmaceuticals Inc increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was -$2.18M, a 42357.71% decline year-over-year.
- Curanex Pharmaceuticals Inc increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was -$2.33M.
- Curanex Pharmaceuticals Inc increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was $8.58M.
- Curanex Pharmaceuticals Inc increase (decrease) in prepaid expense for fiscal 2025 was $6.25M, a 530289.99% increase from fiscal 2024.
- Curanex Pharmaceuticals Inc increase (decrease) in prepaid expense for fiscal 2024 was $1.18K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$4.40M 10-Q · filed 2026-08-14 | -$6.73M derived: sum of 3 quarters · filed 2026-08-14 | $1.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$2.18M 10-Q · filed 2026-05-14 | -$4.51M derived: sum of 2 quarters · filed 2026-05-14 | $4.07M derived: sum of 3 quarters · filed 2026-05-14 | $4.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.25M derived: sum of 2 quarters · filed 2026-03-30 | $6.25M derived: sum of 3 quarters · filed 2026-08-14 | $6.25M 10-K · filed 2026-03-30 |
| 2025-09-30 | $8.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $8.58M derived: sum of 2 quarters · filed 2026-08-14 | $8.59M 10-Q · filed 2025-11-17 | |
| 2025-06-30 | -$47.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $5.11K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $5.16K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $1.18K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |